Compositions and methods for hardening
AssigneeSPI Pharma, Inc.
InventorsBrian Wilson, Greg Simon, Graeme Macleod
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to, among other things, compositions and methods for improving hardness without using excessive compression forces, thereby preserving compression-sensitive or pressure-sensitive active ingredients. The present disclosure also relates to compositions and methods for preparing post-compression hardening materials having a high tensile strength at low water activity.
Claims32
1-22. (canceled)
A dose form selected from a chewable, a tablet, a minitablet, a wafer, a compact, a lozenge, a granule, a hard capsule plug, an effervescent, and a ribbon, wherein the dose form comprises an excipient system comprising two or more polyols, and one or more other excipients selected from the group consisting of sodium stearyl fumarate, magnesium stearate, micro crystalline cellulose, dicalcium phosphate, cellulose, hydroxypropyl cellulose, colloidal silica, fumed silica, PEG, talc, flavors, colors, calcium carbonate, cyclodextrin, gelatin, cellulose ethers, sweeteners, stearic acid, citric acid, hydrogenated castor oil, glyceryl monostearate, methylcellulose, polysorbate, titanium dioxide, starch, a super disintegrant, alginate, lactose, maltose, sucrose, glucose, polydextrose, dextrose, and PVP, wherein upon further processing or storage, a hardness value of the dose form increases by at least 50%.
(canceled)
(canceled)
30-31. (canceled)
(canceled)
(canceled)
39-41. (canceled)
43-47. (canceled)
A solid dosage form, comprising:
- (i) two or more polyols co-processed to form a homogeneous material, wherein the two or more polyols are independently selected from the group consisting of mannitol, sorbitol, maltitol, xylitol, erythritol, hydrogenated starch hydrolysates, isomalt, and lactitol, wherein the two or more polyols comprises a first polyol present in an amount of about 5 wt % to about 25 wt %, and a second polyol present in an amount of 5 wt % to 25 wt %;
- and
- (ii) one or more compression-sensitive or pressure-sensitive active ingredients,
- wherein (1) a hardness (in kiloponds, kP) of the solid dosage form per compression force (in kilonewtons, kN) used to form the solid dosage form is at least about 2.0 after less than about 24 hours of storage, and/or (2) the solid dosage form comprises a first hardness at time t0 and a second hardness at time t1 that is at least about 50% greater than the first hardness, wherein the time t1 is about 4 hours, about 8 hours, about 12 hours, about 16 hours, about 20 hours, or about 24 hours after the time t0.
51-52. (canceled)
(canceled)
56-62. (canceled)
67-96. (canceled)
Dependencies are inferred from the claim text.